RxDoctor Payments Data

Sucharitha Shanmugam, MD

Rheumatology · Phoenixville, PANPI 1295941425

Payments from drug & device makers

$17,528in general payments, 2019–2025

Across 573 payments — averaging $30.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$5K
  • AbbVie$3K
  • Amgen$2K
  • UCB, Inc.$796
  • AstraZeneca$726
  • GSK$696
  • plus $4K from 31 others

What the payments were for

  • Consulting fees$5,06029%
  • Grants$2401%
  • Travel & lodging$1471%
  • Food & beverage$11,79967%
  • Education$2832%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,528 in reported general payments places this provider in the 70th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$3,466,235
Medicare patients
870
Services billed
293,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept42$318,770
Humira(Cf) PenAdalimumab12$77,663
TymlosAbaloparatide16$40,426
ProliaDenosumab23$38,954
MethotrexateMethotrexate Sodium204$5,450
Hydroxychloroquine Sulfate103$4,579
Celecoxib60$2,150
Prednisone289$2,045
Alendronate Sodium83$886
Allopurinol62$834
Leflunomide24$815
Colchicine19$651
Duloxetine Hcl25$591
Pregabalin16$436
Methylprednisolone13$330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$236$40,42616 claims
AmgenProlia$2,345$38,95423 claims
Scilex Pharmaceuticals Inc.Colchicine$20$65119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 351 rheumatology providers in Pennsylvania.

Other rheumatology in Phoenixville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →